Research programme: anti-TAG-72 monoclonal antibody - Quest PharmaTech

Drug Profile

Research programme: anti-TAG-72 monoclonal antibody - Quest PharmaTech

Alternative Names: Anti-TAG-72 monoclonal antibody - Quest PharmaTech; AR54; MAb B72.3; Monoclonal antibody B72.3; OncoRex

Latest Information Update: 06 Mar 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Quest PharmaTech
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
  • 23 Jul 2013 Quest PharmaTech enters a long-term strategic agreement with AD Biotech to co-develop research and technologies of both companies
  • 10 Jun 2013 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top